{"entity":{"id":"nct07021261","kind":"trial","name":"Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients","aka":[],"tldr":"A phase 3 trial of utidelone and capecitabine in triple-negative breast cancer, run by Fudan University, not yet recruiting.","summary":"Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients is a phase 3, randomised interventional study registered as NCT07021261 by Fudan University, with a registry enrolment figure of 440 participants, started 2025-06-16 and due to reach its primary completion in 2030-06-16. Interventions recorded: Utidelone plus capecitabine; Capecitabine. Conditions listed: Breast Cancer; TNBC. Triple-negative eligibility wording from the registry: \"Triple-Negative Breast Cancer Confirmation\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07021261","url":"https://clinicaltrials.gov/study/NCT07021261"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["utidelone","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07021261","phase":"3","setting":"A Multicenter, Open-Label, Randomized, Phase III Study Comparing UTD2 Combined With Capecitabine to Capecitabine Monotherapy as Adjuvant Therapy for Triple-Negative Breast Cancer Patients Who Did Not Achieve Pathological Complete Response","sponsor":"Fudan University","participation":[{"nct":"NCT07021261","source":"https://clinicaltrials.gov/study/NCT07021261","fetchedAt":"2026-10-07T16:55:21.080Z","studySha256":"f53694afea75ca024bf08488c038c298fdcfdfe675d1201879116ea4185cc342","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2025-06-13","leadSponsor":"Fudan University","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"70 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":440,"enrolmentType":"ESTIMATED","siteCount":0,"recruitingSiteCount":0}],"started":"2025-06-16","startedType":"estimated","enrolled":440,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07021261/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"utidelone","kind":"drug","name":"Utidelone","route":"/drugs/utidelone/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}